Positive opinion by European Medicines Agency paves way for IPM to pursue approvals of dapivirine ring in African countries MTN studies of ring’s safety in girls and pregnant and breastfeeding women taking place in parallel A vaginal ring intended to be used for a month at a time has moved one step closer to potentially becoming a new HIV prevention method for cisgender women in sub-Saharan Africa, who despite being the face of the epidemic, have few options for protecting themselves against getting infected.
Strict Adherence to Daily PrEP is Especially Important in Pregnancy, Investigators Conclude. Among African adolescent girls and young women who took HIV pre-exposure prophylaxis (PrEP) daily, levels of the PrEP drug tenofovir were more than 30% lower in those who were pregnant than in those who had recently given birth. All 40 study participants took PrEP under direct observation, confirming their near-perfect adherence. PrEP drug levels were lower to a similar degree in the pregnant African adolescent girls and young women compared to American men and non-pregnant, non-lactating women who took PrEP daily under direct observation in an earlier study. These findings from the NIH-funded IMPAACT 2009 study were reported today at the Conference on Retroviruses and Opportunistic Infections (CROI)
Wits RHI Shandukani Research Centre is pleased to inform the public and all relevant stakeholders that the site has successfully enrolled its first participant into MTN 042, or DELIVER, a Phase 3b safety study of the monthly dapivirine vaginal ring and Truvada as daily oral pre-exposure prophylaxis (PrEP) in pregnant women.
Mexico City, 24 July 2019 – South African study shows that dolutegravir-containing regimens perform as well as the current efavirenz-containing one used for first-line antiretroviral treatment (ART) in South Africa and most of Africa. These data are important in showing how dolutegravir and a new form of tenofovir (called tenofovir alafenamide or TAF) perform in African populations, and in providing the scientific backing for the move to dolutegravir-containing regimens from efavirenz-containing ones worldwide. The initial study results are also published today in the most prestigious medical journal in the world, The New England Journal of Medicine.
ECHO finds no substantial difference in HIV risk among DMPA-IM,copper IUD, and LNG implant users. DURBAN (South Africa) 13 June 2019 – A pivotal clinical trial to address a long-standing question about the relationship between hormonal contraceptive use and the risk of HIV acquisition has found no substantial difference in HIV risk among 7,829 African women who were randomly assigned to use one of three highly effective methods of contraception.
Wits RHI is proud to announce the launch of a USAID-funded five year (2018 - 2023) School Based HIV and Gender Based Violence (GBV) Prevention Programme.Wits RHI will work directly with the Department of Basic Education (DBE) to reduce the incidence of HIV, tuberculosis (TB) infections and violence among in-school adolescent girls and boys, aged between 9 – 19 years, across five provinces in South Africa.
Wits RHI is the successful recipient of two awards from the Bill and Melinda Gates Foundation and the National Health and Medical Research Council of Australia for over the next five years. These will fund a study to evaluate the impact of 2-dose and 1-dose human papillomavirus vaccination schedules on community level HPV prevalence in South African adolescent girls. Cervical cancer is caused by human papillomavirus (HPV) and is the leading cancer among women aged 15–44.
The Wits RHI Key Populations Programme is the successful recipient of a 5-year USAID Award for advancing the South African HIV Response for Key Populations, Sex Workers, and Transgender individuals. Sex workers and transgender individuals remain marginalised in public healthcare. In South Africa, between 40 percent and 88 percent of sex workers are HIV positive. Transgender women globally are 50 times more likely to be HIV positive than the general population. This award will change the status quo for key populations in South Africa through increasing access to health care and enhancing competency of health service providers to tailor responses to their needs.
The Minister of Health, Dr Aaron Motsoaledi, has appointed members of the South African Health Products Regulatory Authority (SAHPRA) Board. SAHPRA replaces the Medicines Control Council (MCC). The scope of the new Authority has expanded to include not only medicines, but also medical devices including in vitro diagnostics, and aspects of radiation control.
A highly effective oral medication to prevent HIV will be provided to young women in South Africa at high risk of getting the virus, as part of a sexual and reproductive health access project launched today by the Wits Reproductive Health and HIV Institute (Wits RHI) and Unitaid.